NCT00303849View on ClinicalTrials.gov

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 15, 2005

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Anaplastic OligoastrocytomaAnaplastic OligodendrogliomaMixed GliomaOligoastrocytoma
Interventions
DRUG

Carboplatin

Given IA

DRUG

Etoposide

Given IV

DRUG

Etoposide Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mannitol

Given IA

DRUG

Melphalan

Given IA

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Sodium Thiosulfate

Given IV

Trial Locations (2)

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT00303849 - Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | Biotech Hunter | Biotech Hunter